Skip to main content
Clinical Trials/ISRCTN62033854
ISRCTN62033854
Completed
未知

Magnetic resonance imaging to characterise invasive phenotypes in cerebral gliomas: an observational prospective cohort study

Cambridge University Hospitals NHS Foundation Trust (UK)0 sites145 target enrollmentMarch 4, 2011

Overview

Phase
未知
Intervention
Not specified
Conditions
Glioblastomas
Sponsor
Cambridge University Hospitals NHS Foundation Trust (UK)
Enrollment
145
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 4, 2011
End Date
December 31, 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Imaging appearances of a high grade glioma
  • 2\. Likely to be suitable for radiotherapy (60 Gy) with concomitant and adjuvant temozolomide
  • 3\. World Health Organization (WHO) performance status (PS) grade 0 or 2
  • 4\. Aged 18 \- 75 years, either sex
  • 5\. Resection or biopsy (although only those suitable for maximal resection will be considered for the MALTING Trial)
  • Patients for the MALTING Trial will be felt by their consultant neurosurgeon to be suitable for 5\-aminolevulinic acid (5\-ALA) fluorescence\-guided resection with insertion of carmustine wafers.

Exclusion Criteria

  • 1\. Unsuitable for a contrast\-enhanced MRI (MR unsafe metallic implants, claustrophobia, allergy to gadolinium contrast agent or severe renal impairment)
  • 2\. Pregnant
  • 3\. Allergic to aminolevulinic acid
  • 4\. Suffering from porphyria. Care will be taken if the patient is taking other photosensitising drugs.

Outcomes

Primary Outcomes

Not specified

Similar Trials